Do analysts recommend ABP or SNGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, ABP or SNGX?

Soligenix is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Soligenix N/A N/A -$11.08M -$0.98 N/A

Is ABP or SNGX more profitable?

Abpro's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Soligenix N/A -180.25% -107.46%

Do analysts recommend ABP or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ABP or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is ABP or LNAI more profitable?

Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Lunai Bioworks N/A N/A -1,617.76%

Do analysts recommend ABP or LIMN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, ABP or LIMN?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Liminatus Pharma N/A N/A -$10.21M -$23.50 N/A

Is ABP or LIMN more profitable?

Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Liminatus Pharma N/A N/A -256.58%

Do analysts rate ABP or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABP or XBIO more profitable?

Abpro has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Abpro's return on equity of 0.00% beat Xenetic Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Xenetic Biosciences -75.90% -40.62% -34.97%

Do analysts prefer ABP or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABP or XTLB more profitable?

Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% XTL Biopharmaceuticals N/A N/A N/A

Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 10/8/2026

Compare

ABP vs. SNGX, LNAI, LIMN, XBIO, and XTLB

Should you buy Abpro stock or one of its competitors? Abpro's main competitors and comparable companies include Soligenix (SNGX), Lunai Bioworks (LNAI), Liminatus Pharma (LIMN), Xenetic Biosciences (XBIO), and XTL Biopharmaceuticals (XTLB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abpro compare to Soligenix?

Abpro (NASDAQ:ABP) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

23.3% of Abpro shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Comparatively, 1.9% of Soligenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Soligenix is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Soligenix	N/A	N/A	-$11.08M	-$0.98	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Abpro's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Soligenix	N/A	-180.25%	-107.46%

In the previous week, Soligenix had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Soligenix and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Soligenix	Neutral

Summary

Abpro beats Soligenix on 6 of the 9 factors compared between the two stocks.

How does Abpro compare to Lunai Bioworks?

Abpro (NASDAQ:ABP) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

In the previous week, Lunai Bioworks had 3 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Lunai Bioworks and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled Lunai Bioworks'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Lunai Bioworks	Neutral

Lunai Bioworks is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Lunai Bioworks	N/A	N/A	-1,617.76%

23.3% of Abpro shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Abpro beats Lunai Bioworks on 5 of the 8 factors compared between the two stocks.

How does Abpro compare to Liminatus Pharma?

Abpro (NASDAQ:ABP) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Liminatus Pharma had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Liminatus Pharma and 0 mentions for Abpro. Liminatus Pharma's average media sentiment score of 1.32 beat Abpro's score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Liminatus Pharma	Positive

23.3% of Abpro shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 19.4% of Liminatus Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Liminatus Pharma	N/A	N/A	-256.58%

Liminatus Pharma is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$23.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Abpro beats Liminatus Pharma on 5 of the 9 factors compared between the two stocks.

How does Abpro compare to Xenetic Biosciences?

Abpro (NASDAQ:ABP) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

23.3% of Abpro shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Abpro has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Abpro's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Xenetic Biosciences has higher revenue and earnings than Abpro. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Xenetic Biosciences	$2.98M	1.64	-$2.68M	-$1.16	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Xenetic Biosciences had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Xenetic Biosciences and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled Xenetic Biosciences'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
Xenetic Biosciences	Neutral

Summary

Abpro beats Xenetic Biosciences on 6 of the 11 factors compared between the two stocks.

How does Abpro compare to XTL Biopharmaceuticals?

Abpro (NASDAQ:ABP) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for XTL Biopharmaceuticals and 0 mentions for Abpro. Abpro's average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Abpro	Neutral
XTL Biopharmaceuticals	Neutral

23.3% of Abpro shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 13.7% of Abpro shares are owned by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
XTL Biopharmaceuticals	N/A	N/A	N/A

XTL Biopharmaceuticals has higher revenue and earnings than Abpro. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
XTL Biopharmaceuticals	$450K	10.72	-$6.97M	-$0.64	N/A

Summary

XTL Biopharmaceuticals beats Abpro on 6 of the 9 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.36%
P/E Ratio	-0.12	13.42	274.15	26.16
Price / Sales	N/A	1,237.94	590.34	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	-0.06	17.17	11.21	6.34
Net Income	-$7.23M	-$22.69M	$3.50B	$381.90M
7 Day Performance	N/A	-1.33%	-0.90%	-1.41%
1 Month Performance	N/A	-8.44%	-4.44%	-3.48%
1 Year Performance	-90.54%	14.02%	6.96%	1.16%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
SNGX Soligenix	0.8146 of 5 stars	$0.35 -1.3%	N/A	-79.7%	$5.31M	$120K	N/A	14
LNAI Lunai Bioworks	0.1535 of 5 stars	$1.09 -3.5%	N/A	-87.6%	$5.12M	N/A	N/A	29	News Coverage Gap Up
LIMN Liminatus Pharma	1.2147 of 5 stars	$3.88 +4.9%	N/A	-95.1%	$4.97M	N/A	N/A	1
XBIO Xenetic Biosciences	0.8938 of 5 stars	$2.21 +4.2%	N/A	-77.5%	$4.86M	$2.98M	N/A	2	Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. SNGX, LNAI, LIMN, XBIO, and XTLB

How does Abpro compare to Soligenix?

Summary

How does Abpro compare to Lunai Bioworks?

Summary

How does Abpro compare to Liminatus Pharma?

Summary

How does Abpro compare to Xenetic Biosciences?

Summary

How does Abpro compare to XTL Biopharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. SNGX, LNAI, LIMN, XBIO, and XTLB

How does Abpro compare to Soligenix?

Do insiders and institutionals hold more shares of ABP or SNGX?

Which has higher earnings & valuation, ABP or SNGX?

Do analysts recommend ABP or SNGX?

Is ABP or SNGX more profitable?

Does the media prefer ABP or SNGX?

Summary

How does Abpro compare to Lunai Bioworks?

Does the media favor ABP or LNAI?

Which has stronger valuation and earnings, ABP or LNAI?

Do analysts recommend ABP or LNAI?

Is ABP or LNAI more profitable?

Do institutionals and insiders hold more shares of ABP or LNAI?

Summary

How does Abpro compare to Liminatus Pharma?

Does the media prefer ABP or LIMN?

Do institutionals and insiders hold more shares of ABP or LIMN?

Is ABP or LIMN more profitable?

Which has better earnings & valuation, ABP or LIMN?

Do analysts recommend ABP or LIMN?

Summary

How does Abpro compare to Xenetic Biosciences?

Do institutionals & insiders hold more shares of ABP or XBIO?

Is ABP or XBIO more profitable?

Which has better earnings & valuation, ABP or XBIO?

Do analysts rate ABP or XBIO?

Does the media refer more to ABP or XBIO?

Summary

How does Abpro compare to XTL Biopharmaceuticals?

Do analysts prefer ABP or XTLB?

Does the media refer more to ABP or XTLB?

Do insiders & institutionals hold more shares of ABP or XTLB?

Is ABP or XTLB more profitable?

Which has stronger valuation and earnings, ABP or XTLB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools